Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Leuk Lymphoma. 2016 Jan 19;57(9):2100–2108. doi: 10.3109/10428194.2015.1135435

Figure 2.

Figure 2

Midostaurin, bortezomib combined with MEC upregulates pri-miR-29b, and downregulates FLT3 and miR-155 expression in AML patients. BM samples were collected prior treatment (Day 0) or posttreatment on Days 3 or 8 from patients receiving only midostaurin and bortezomib (Mid & Bortz) and those treated with midostaurin, bortezomib and MEC (Mid, Bortz & MEC). Samples were analyzed by quantitative RT-PCR for expression levels of (A) pri-miR-29b; (B) FLT3 mRNA; (C) miR-155. Data are normalized by the internal controls and presented as mean ± SE for each group of patients. *p<0.05; **p<0.01, when compared with the pretreatment basal level of each group.